Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Robust strategies in nuclear-targeted cancer therapy based on functional nanomaterials

Qin Xiaofei; Zhang Hanyi; Xing Xin; Wang Peng; Yan Jiaqi; Liu Daishun; Gong Qiuyu; Zhang Renshuai; Zhang Hongbo

Robust strategies in nuclear-targeted cancer therapy based on functional nanomaterials

Qin Xiaofei
Zhang Hanyi
Xing Xin
Wang Peng
Yan Jiaqi
Liu Daishun
Gong Qiuyu
Zhang Renshuai
Zhang Hongbo
Katso/Avaa
1-s2.0-S0264127522006219-main.pdf (5.414Mb)
Lataukset: 

ELSEVIER SCI LTD
doi:10.1016/j.matdes.2022.110999
URI
https://www.sciencedirect.com/science/article/pii/S0264127522006219
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022091258803
Tiivistelmä
Nucleus, as the machinery for genome transcription, play prominent roles to support the fundamental cel-lular functions, the destruction of any of these specific parts would significantly modulate the cell function. Therefore, troumendous drug delivery systems with enhanced nucleus targeting ability have been studied for nucleus-related disease regulation. The purpose of this review is to sort out the fundamental nuclear tar-geting strategy, especially the active mechanism of various nuclear targeting ligands and their extensive applications based on cancer targeting therapy. Various nuclear targeting ligands are first introduced to understand their nuclear entry mechanism. Next, to overcome biological barriers and avoid the serum pro-tein absorption, diverse robust delivery strategies based on different nuclear targeting ligands are dis-cussed. Moreover, other sophisticated carrier systems with enhanced nuclear entry, while without nuclear targeting ligands are also assembled. At the end the challenges and future opportunities in the field of nuclear targeting nanotherapeutics are tentatively proposed, to speed up their clinical translation. (c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
Kokoelmat
  • Rinnakkaistallenteet [27094]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste